Trial Information
Generic NameRisperidoneProduct NameRISPERDAL®Therapeutic AreaBehaviors and Mental DisordersEnrollment267% Female44%% White72%
Product ClassAtypical AntipsychoticsSponsor Protocol NumberRIS-USA-239/CR006052Data PartnerJohnson & JohnsonCondition StudiedBipolar DisorderMean/Median Age (Years)39
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available
Approved Data Requests Associated with this Trial
- 2024-0440 : Network analysis of mixed states in bipolar disorders
- 2024-0244 : Reevaluating Treatment Response Prediction in Mental Health: A Study on Generalizability
- 2022-5090 : Consistency checks to improve measurement with the Young Mania Rating Scale (YMRS)
- 2022-4992 : Temporal trajectories of side-effects associated with antipsychotic treatment ? An individual participant data meta-analysis
- 2021-4575 : A NOVEL METHOD TO SUMMARIZE SAFETY IN CLINICAL TRIALS USING PHARMACOLOGICAL CLASS-RELATED RISKS IN FAERS
- 2019-4080 : Explainable Artificial Intelligence Models for Personalized Prediction of Treatment Response in Neurobehavioral Disorders
- 2019-3978 : Safety of Risperidone and Paliperdone in schizophrenia and bipolar disorder diagnosed patients - a systematic review and meta-analysis
- 2019-3958 : Machine Learning for predicting treatment efficacy and clinical categorizations across mental health disorders.
- 2019-3827 : Prediction of outcome and adverse events in antipsychotic treatment
- 2017-1846 : Discontinuation symptoms in antipsychotics: Individual patient level analyses of randomized controlled trials
- 2016-0880 : Incidence of death and other SAEs related to second generation antipsychotic or placebo treatment in RCTs - a systematic review and meta-analysis